Ranbaxy and Pfenex to Develop a Biosimilar Therapeutic Protein

Ranbaxy Laboratories Limited (Gugaon, India) will develop an undisclosed biosimilar therapeutic produced in the Pfenex platform, a Pseudomonas-based recombinant protein expression technology developed by Pfenex Inc. (San Diego, CA).

Ranbaxy and Pfenex scientists will collaborate on developing the production strains and the process that will be used to manufacture the product in support of clinical development and commercial production.

Under the terms of the agreement, Pfenex is eligible to receive maintenance fees, milestone payments, and royalty payments on any product sales derived from the agreement.